Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome

Patients with MDS are clinically subdivided into lower-risk (very low/low/intermediate risk) and higher-risk (high/very high risk) disease according to the revised International Prognostic Scoring System (IPSS-R) risk score [1,2]. Patients with lower-risk MDS are affected primarily by symptoms of chronic anemia and fatigue [3]. Patients with neutropenia and thrombocytopenia are at increased risk for infection, bleeding, and also progression to acute myelogenous leukemia [2]. In a study of patients with lower-risk MDS, hemoglobin level was the most important independent predictor of health-related quality of life [4].

Source: Biology of Blood and Marrow Transplantation - July 22, 2020 Category: Hematology Authors: Polona Novak, Tatjana Zabelina, Christine Wolschke, Francis Ayuk, Maximilian Christopeit, Nicolaus Kr öger Source Type: research